Uniplan Investment Counsel Inc. lowered its stake in shares of Flexion Therapeutics Inc (NASDAQ:FLXN) by 12.0% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 95,965 shares of the specialty pharmaceutical company’s stock after selling 13,038 shares during the quarter. Uniplan Investment Counsel Inc. owned 0.25% of Flexion Therapeutics worth $1,795,000 at the end of the most recent quarter.

Other institutional investors also recently made changes to their positions in the company. Rubric Capital Management LP grew its holdings in Flexion Therapeutics by 7.7% during the third quarter. Rubric Capital Management LP now owns 2,125,000 shares of the specialty pharmaceutical company’s stock worth $39,759,000 after buying an additional 151,286 shares in the last quarter. Bank of America Corp DE grew its stake in Flexion Therapeutics by 66.7% in the 2nd quarter. Bank of America Corp DE now owns 168,233 shares of the specialty pharmaceutical company’s stock valued at $4,349,000 after purchasing an additional 67,284 shares during the period. Alps Advisors Inc. grew its stake in Flexion Therapeutics by 8.5% in the 2nd quarter. Alps Advisors Inc. now owns 54,622 shares of the specialty pharmaceutical company’s stock valued at $1,412,000 after purchasing an additional 4,272 shares during the period. Ardsley Advisory Partners grew its stake in Flexion Therapeutics by 14.4% in the 2nd quarter. Ardsley Advisory Partners now owns 595,000 shares of the specialty pharmaceutical company’s stock valued at $15,381,000 after purchasing an additional 75,000 shares during the period. Finally, BlackRock Inc. grew its stake in Flexion Therapeutics by 8.3% in the 2nd quarter. BlackRock Inc. now owns 2,829,477 shares of the specialty pharmaceutical company’s stock valued at $73,144,000 after purchasing an additional 217,510 shares during the period.

In other news, insider Michael D. Clayman purchased 5,000 shares of the company’s stock in a transaction dated Friday, November 9th. The shares were purchased at an average price of $17.10 per share, with a total value of $85,500.00. Following the transaction, the insider now directly owns 83,295 shares of the company’s stock, valued at $1,424,344.50. The purchase was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CFO David Arkowitz purchased 4,000 shares of the company’s stock in a transaction dated Friday, November 9th. The shares were purchased at an average cost of $16.56 per share, for a total transaction of $66,240.00. Following the transaction, the chief financial officer now directly owns 48,250 shares in the company, valued at $799,020. The disclosure for this purchase can be found here. 14.59% of the stock is owned by corporate insiders.

Shares of NASDAQ:FLXN opened at $15.74 on Wednesday. The firm has a market capitalization of $617.44 million, a price-to-earnings ratio of -3.78 and a beta of 1.18. The company has a quick ratio of 8.74, a current ratio of 8.88 and a debt-to-equity ratio of 1.02. Flexion Therapeutics Inc has a 1 year low of $13.36 and a 1 year high of $29.10.

Flexion Therapeutics (NASDAQ:FLXN) last announced its quarterly earnings data on Wednesday, November 7th. The specialty pharmaceutical company reported ($1.15) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.24) by $0.09. The firm had revenue of $6.99 million during the quarter, compared to the consensus estimate of $5.93 million. Flexion Therapeutics had a negative return on equity of 88.21% and a negative net margin of 1,346.87%. On average, equities analysts forecast that Flexion Therapeutics Inc will post -4.64 EPS for the current fiscal year.

A number of research analysts have issued reports on FLXN shares. BidaskClub upgraded Flexion Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Friday, October 12th. Zacks Investment Research upgraded Flexion Therapeutics from a “hold” rating to a “buy” rating and set a $25.00 price objective for the company in a research note on Friday, August 10th. Wells Fargo & Co set a $39.00 price objective on Flexion Therapeutics and gave the company a “buy” rating in a research note on Monday, October 22nd. Finally, ValuEngine upgraded Flexion Therapeutics from a “hold” rating to a “buy” rating in a research note on Tuesday, October 2nd. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and four have assigned a buy rating to the company’s stock. Flexion Therapeutics has a consensus rating of “Hold” and an average target price of $36.20.

TRADEMARK VIOLATION NOTICE: “Uniplan Investment Counsel Inc. Sells 13,038 Shares of Flexion Therapeutics Inc (FLXN)” was originally posted by Watch List News and is the property of of Watch List News. If you are viewing this piece on another site, it was illegally copied and republished in violation of United States and international copyright & trademark law. The correct version of this piece can be viewed at https://www.watchlistnews.com/uniplan-investment-counsel-inc-sells-13038-shares-of-flexion-therapeutics-inc-flxn/2662849.html.

Flexion Therapeutics Profile

Flexion Therapeutics, Inc, a biopharmaceutical company, focuses on the development and commercialization of anti-inflammatory and analgesic therapies for the treatment of patients with musculoskeletal conditions. It lead product candidate includes Zilretta, an intra-articular injection for the management of osteoarthritis (OA) pain of the knee.

Featured Article: What are the economic characteristics of a bear market?

Institutional Ownership by Quarter for Flexion Therapeutics (NASDAQ:FLXN)

Receive News & Ratings for Flexion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Flexion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.